Dashboard
Manage Tickers

RYTM


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

rhythm-pharmaceuticals-signs-agreements-with-five-canadian-provinces-federal-non-insured-health-benefits-program-for-public-reimbursement-of-imcivree-for-weight-management
Rhythm Pharmaceuticals Signs Agreements Wi...
11/05/2025 21:15:10

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the li...

needham-maintains-buy-on-rhythm-pharmaceuticals-raises-price-target-to-122
Needham Maintains Buy on Rhythm Pharmaceut...
11/04/2025 17:06:06

Needham analyst Joseph Stringer maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $...

rhythm-pharmaceuticals-q3-eps-082-misses-073-estimate-sales-51298m-beat-50705m-estimate
Rhythm Pharmaceuticals Q3 EPS $(0.82) Miss...
11/04/2025 12:00:36

Rhythm Pharmaceuticals (NASDAQ:RYTM) reported quarterly losses of $(0.82) per share which missed the analyst consensus estimate...

earnings-scheduled-for-november-4-2025
Earnings Scheduled For November 4, 2025
11/04/2025 11:12:08

rhythm-pharmaceuticalss-earnings-a-preview
Rhythm Pharmaceuticals's Earnings: A Preview
11/03/2025 19:01:18

goldman-sachs-maintains-buy-on-rhythm-pharmaceuticals-lowers-price-target-to-139
Goldman Sachs Maintains Buy on Rhythm Phar...
10/17/2025 17:21:28

Goldman Sachs analyst Corinne Jenkins maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and lowers the price target ...

morgan-stanley-maintains-overweight-on-rhythm-pharmaceuticals-raises-price-target-to-129
Morgan Stanley Maintains Overweight on Rhy...
10/16/2025 18:01:46

Morgan Stanley analyst Jeffrey Hung maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and raises the price ta...

hc-wainwright--co-maintains-buy-on-rhythm-pharmaceuticals-raises-price-target-to-110
HC Wainwright & Co. Maintains Buy on Rhyth...
09/29/2025 10:31:24

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Rhythm Pharmaceuticals (NASDAQ: RYTM) with a Buy and raises the...

morgan-stanley-maintains-overweight-on-rhythm-pharmaceuticals-raises-price-target-to-122
Morgan Stanley Maintains Overweight on Rhy...
09/25/2025 17:54:10

Morgan Stanley analyst Jeffrey Hung maintains Rhythm Pharmaceuticals (NASDAQ: RYTM) with a Overweight and raises the price t...

jmp-securities-maintains-market-outperform-on-rhythm-pharmaceuticals-raises-price-target-to-142
JMP Securities Maintains Market Outperform...
09/25/2025 13:13:08

JMP Securities analyst Jonathan Wolleben maintains Rhythm Pharmaceuticals (NASDAQ: RYTM) with a Market Outperform and raises...

goldman-sachs-maintains-buy-on-rhythm-pharmaceuticals-raises-price-target-to-138
Goldman Sachs Maintains Buy on Rhythm Phar...
09/24/2025 18:01:13

Goldman Sachs analyst Corinne Jenkins maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target ...

peering-into-rhythm-pharmaceuticalss-recent-short-interest
Peering Into Rhythm Pharmaceuticals's Rece...
09/11/2025 17:01:03

rhythm-pharmaceuticals-announces-the-fda-has-accepted-its-supplemental-new-drug-application-for-setmelanotide-to-treat-acquired-hypothalamic-obesity
Rhythm Pharmaceuticals Announces The FDA H...
08/20/2025 20:03:53

U.S. Food and Drug Administration accepts sNDA for filing with priority review; sets PDUFA goal date of December 20, 2025 --– E...

hc-wainwright--co-maintains-buy-on-rhythm-pharmaceuticals-raises-price-target-to-100
HC Wainwright & Co. Maintains Buy on Rhyth...
08/07/2025 11:58:45

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the ...

12-analysts-have-this-to-say-about-rhythm-pharmaceuticals
12 Analysts Have This To Say About Rhythm ...
08/06/2025 21:04:06

morgan-stanley-maintains-overweight-on-rhythm-pharmaceuticals-raises-price-target-to-109
Morgan Stanley Maintains Overweight on Rhy...
08/06/2025 16:30:58

Morgan Stanley analyst Jeffrey Hung maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and raises the price ta...

jmp-securities-maintains-market-outperform-on-rhythm-pharmaceuticals-raises-price-target-to-135
JMP Securities Maintains Market Outperform...
08/06/2025 15:19:13

JMP Securities analyst Jonathan Wolleben maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Market Outperform and raises ...

guggenheim-maintains-buy-on-rhythm-pharmaceuticals-raises-price-target-to-120
Guggenheim Maintains Buy on Rhythm Pharmac...
08/06/2025 14:56:41

Guggenheim analyst Seamus Fernandez maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target fr...

rhythm-pharmaceuticals-q2-eps-075-misses-064-estimate-sales-4850m-beat-4372m-estimate
Rhythm Pharmaceuticals Q2 EPS $(0.75) Miss...
08/05/2025 11:03:46

Rhythm Pharmaceuticals (NASDAQ:RYTM) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate...

Core News & Articles
Earnings Scheduled For August 5, 2025
08/05/2025 08:32:54

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION